Travere Therapeutics will be asking itself that question after a second attempt to gun for accelerated approval was rejected by the FDA, the company announced Wednesday afternoon. The former Martin Shkreli biotech had attempted to push through its lead drug, sparsentan, to a speedy OK in a rare kidney disease, but regulators prefer the more methodical, full approval route.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,